To date, a large number of LSD1 inhibitors with varieties of structures have been developed, and several synthetic inhibitors of LSD1 such as TCP, ORY-1001, GSK2879552, and IMG-7289, are currently under investigation in clinical trials for treatment of hematologic malignancies, lung cancers, etc. In addition, as a rich source of bioactive molecules, several natural products such as mangostin, catechol, and baicalin have been successively identified as novel LSD1 inhibitors with moderate inhibitory activities (20-23). This evidence concerns the gene KDM1A and hematologic disorder.